Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges

Autoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper un...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2021
Language:English
Physical Description:1 electronic resource (266 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04477nam-a2201117z--4500
001 993545643204498
005 20231214133008.0
006 m o d
007 cr|mn|---annan
008 202201s2021 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000042395 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/77076 
035 |a (EXLCZ)995400000000042395 
041 0 |a eng 
100 1 |a Feist, Eugen  |4 edt 
245 1 0 |a Systemic Autoinflammatory Diseases-Clinical Rheumatic Challenges 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2021 
300 |a 1 electronic resource (266 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Autoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper understanding of closely linked diseases, namely, inflammasomopathies, interferonopathies, Relo-pathies, and proteasome associated syndromes. These insights have not only improved their classification but also helped to identify new treatment targets of pro-inflammatory cytokines, including IL-1ß, IL-6, interferon-, and TNF-alpha. Nevertheless, there is still a high medical need, especially in reliable outcome measures, for confirmation of data from controlled clinical trials and, finally, also for long-term experience from registers. This issue welcomes all types of papers on the broad spectrum of clinical characteristics, prognosis, pathophysiology, and treatment of autoinflammatory diseases. The goal of this Special Issue is to further raise awareness of autoinflammatory processes and to better separate them from well-established autoimmune diseases. It is clear that we have entered a new age in this complex field, linking rheumatology even closer to immunology. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a gout 
653 |a febuxostat 
653 |a colchicine 
653 |a hepatotoxicity 
653 |a prophylaxis 
653 |a myositis 
653 |a inflammatory idiopathic myopathy 
653 |a dysphagia 
653 |a aspiration 
653 |a pneumonia 
653 |a immunoglobulin G4-related orbital disease (IgG4-ROD) 
653 |a orbital lymphoma (OL) 
653 |a computed tomography (CT) 
653 |a Hounsfield unit 
653 |a imaging 
653 |a autoinflammation 
653 |a arthritis 
653 |a CAPS 
653 |a FCAS 
653 |a MWS 
653 |a CINCA 
653 |a NOMID 
653 |a hearing loss 
653 |a urticarial-like rash 
653 |a autoinflammatory disease 
653 |a anti-IL-1 treatment 
653 |a rheumatoid arthritis 
653 |a synovitis 
653 |a neoplasms 
653 |a edema 
653 |a inflammation 
653 |a new genetic variant 
653 |a monogenic autoinflammatory syndrome 
653 |a diagnostic delay 
653 |a anakinra 
653 |a damage index 
653 |a genetic inheritance 
653 |a personalized therapy 
653 |a Interleukin-1 
653 |a autoinflammatory diseases 
653 |a FMF 
653 |a coronavirus 
653 |a SARS-CoV-2 antibody response 
653 |a adult-onset Still's disease 
653 |a autoinflammatory disorder 
653 |a systemic-onset juvenile idiopathic arthritis 
653 |a haemophagocytic lymphohistiocytosis 
653 |a macrophage activation syndrome 
653 |a IFN-γ 
653 |a JAK inhibitor 
653 |a proliferation 
653 |a DNA damage repair 
653 |a γH2AX 
653 |a PBMCs 
653 |a T lymphocytes 
653 |a proteasome 
653 |a autoimmune 
653 |a proteasome-associated autoinflammatory syndrome 
653 |a therapy 
653 |a IL-1 inhibitors 
653 |a NGS 
653 |a SURF 
653 |a spondyloarthritis 
653 |a human leukocyte antigen 
653 |a undifferentiated enthesitis and/or arthritis 
653 |a ASAS classification criteria 
653 |a clinical management 
653 |a canakinumab 
653 |a cytokines 
776 |z 3-0365-2560-2 
776 |z 3-0365-2561-0 
700 1 |a Feist, Eugen  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:39:29 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338005550004498&Force_direct=true  |Z 5338005550004498  |b Available  |8 5338005550004498